Inhibikase Therapeutics
IKT
IKT
17 hedge funds and large institutions have $2.91M invested in Inhibikase Therapeutics in 2023 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 4 closing their positions.
New
Increased
Maintained
Reduced
Closed
more capital invested
Capital invested by funds: $ → $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more ownership
Funds ownership: →
less funds holding
Funds holding: →
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
Holders
17
Holding in Top 10
–
Calls
–
Puts
–
Top Buyers
| 1 | +$2.06M | |
| 2 | +$57.6K | |
| 3 | +$32.7K | |
| 4 |
Renaissance Technologies
New York
|
+$10.6K |
| 5 |
VF
Virtu Financial
New York
|
+$9.37K |
Top Sellers
| 1 | -$15.3K | |
| 2 | -$5.35K | |
| 3 | -$5K | |
| 4 |
RPCONE
Retirement Planning Company of New England
Warwick,
Rhode Island
|
-$217 |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$65 |